DHA.

DHA and EPA are the two long-chain omega-3 fatty acids, and they build into cell membrane phospholipids side by side. DHA is the dominant structural fat of nerve and eye tissue, while EPA is a key precursor the body uses for its own resolution-phase signaling lipids, which is why fish and algal oils carry the pair together.

DHA carries six double bonds, which makes it one of the most oxidation-prone fats both in the body and in the bottle. Vitamin E is the fat-soluble antioxidant that sits in the same membranes and oil and intercepts the lipid peroxidation chain reaction, so it is routinely added to keep DHA from going rancid.

In nerve cell membranes DHA is preferentially built into phosphatidylserine, and a good DHA supply promotes the accumulation of phosphatidylserine in those membranes. The two are a natural molecular pair that together support normal neuronal membrane structure.

DHA is the most abundant fatty acid in the photoreceptor membranes of the retina, while lutein concentrates alongside it as part of the macular pigment. The two have long been formulated together to support the normal structure and light-filtering function of the macula.

DHA is carried in the body mostly esterified into phosphatidylcholine, and choline supplies the headgroup for that molecule. Without adequate choline the DHA has fewer phospholipid carriers to occupy.

DHA has six double bonds and is the most peroxidation-prone fatty acid in the diet. Tocopherol is the chain-breaking antioxidant added to oils and membranes precisely to keep that from happening.

Zeaxanthin concentrates in the central macular pigment while DHA makes up much of the photoreceptor outer segment membrane. They occupy complementary roles in the same tissue.

Astaxanthin spans the lipid bilayer and quenches radicals at both membrane surfaces, which is where DHA sits and where peroxidation starts. It is the carotenoid most often paired with DHA for that reason.

Phosphatidylcholine is the phospholipid backbone DHA is esterified into for transport and membrane insertion. Delivering DHA with its carrier rather than as a free acid changes how much reaches tissue.

Krill oil delivers DHA in phospholipid form, so the two products supply the same fatty acid by different carriers. Doses stack, which matters when a formula counts total DHA.

Reduced CoQ10 works inside the lipid phase of membranes and helps regenerate tocopherol after it has quenched a radical. That recycling loop is what keeps polyunsaturated chains like DHA intact.

Both are fat-soluble and naturally co-occur in fish liver oils, so they share the same lipid vehicle and absorption route. Formulas combine them because one oil base serves both.

Zinc is needed for the desaturase enzymes that elongate shorter omega-3s toward DHA, and for retinal DHA handling. Low zinc status limits how well the body works with the fatty acid it is given.

Ginkgolides antagonise platelet activating factor while DHA shifts the thromboxane to prostacyclin balance. Both lengthen normal platelet aggregation, so the effect is additive at full doses.

Garlic organosulfur compounds reduce normal platelet aggregation through a separate route from omega-3 eicosanoid shifts. Combined, the two effects add rather than cancel.

DHA absorption depends on bile salt micelles, and a strong determinant of how much of a dose is absorbed is how much fat is eaten with it. Medium-chain triglycerides stimulate that response while themselves taking a partly portal route. Human pharmacokinetic work on omega-3 esters shows a meal-fat effect, which is the practical reason to dose with food.

Neither triglyceride-bound nor ethyl-ester DHA is absorbed intact; pancreatic lipase must cleave the fatty acid free first, and it hydrolyses ethyl esters more slowly than triglycerides. Where lipase output is low, less of a given dose is liberated. A lipase-containing enzyme preparation addresses that specific step and does nothing for anyone whose lipase output is already adequate.

Long-chain fatty acids need bile salts to form the mixed micelles that ferry them to the enterocyte brush border. Where bile flow is reduced, fat-soluble absorption falls, which is why bile acid preparations are used alongside oils. The mechanism is established; there is no combination trial cited for DHA specifically.

Lipase works at the oil-water interface, so a finer emulsion means faster hydrolysis of the same amount of oil. Lecithin is a standard emulsifier used to achieve that in liquid and emulsion omega-3 products. Faster hydrolysis is a formulation property and does not by itself change what the fatty acid does once absorbed.

Lecithin phospholipids stabilise a fine oil-in-water dispersion, which keeps a liquid omega-3 product from separating and improves palatability. It also supplies phospholipid that can carry fatty acids in the membrane pool. The gain is delivery and stability, not a different biological effect.

With six double bonds, DHA is among the most oxidation-prone fatty acids in a common supplement, and rancidity is measurable as peroxide and anisidine values. Rosemary extract standardised on carnosic acid is widely used to slow that in oils and often sits alongside tocopherols. It protects the material in the bottle; it makes no claim about the person taking it.

Glutathione peroxidase 4 is the selenoenzyme that reduces phospholipid hydroperoxides inside membranes, which is exactly where DHA sits. Adequate selenium status is therefore part of how a highly unsaturated membrane is maintained. This is settled biochemistry about a maintenance system, not evidence that supplementing both together produces a measured benefit.

Alpha-tocopherol stops the chain reaction that propagates through polyunsaturated membrane lipids and is left as a tocopheroxyl radical; ascorbate at the aqueous interface reduces it back. That recycling is why the two are considered a pair in lipid peroxidation chemistry. Ascorbate together with unbound iron can instead act as a pro-oxidant, so the direction depends on iron status.

Free iron catalyses hydroperoxide breakdown into radicals that propagate along polyunsaturated chains, and DHA with six double bonds is a highly vulnerable substrate. In a formulation this shows up as accelerated rancidity, which is why iron and fish or algal oil are usually kept in separate products or separated by encapsulation. Iron is also a required nutrient for normal neural development, so the interaction is a handling matter rather than a reason to avoid either.

Like iron, unbound copper cycles between oxidation states and initiates peroxidation of unsaturated lipids. Co-formulating a copper salt directly with a DHA-rich oil shortens the shelf life of the oil. Separating the two in the dosage form is the standard answer.

Linoleic acid and alpha-linolenic acid are handled by the same desaturase and elongase set, so a high linoleic intake reduces the flux of the n-3 pathway. Arachidonic acid and DHA also compete for the sn-2 position of membrane phospholipids. This competition is textbook, and it is why background dietary fat composition changes how much a given DHA dose shifts the membrane.

GLA feeds forward through elongation to dihomo-gamma-linolenic acid and arachidonic acid using the same enzymes the n-3 pathway needs. Supplying substantial GLA alongside DHA pushes n-6 derived mediators up while DHA pushes n-3 derived ones. Combined n-6 and n-3 products are common and the competition is the reason their ratio, not just their total, is specified.

Flaxseed oil supplies alpha-linolenic acid, which must pass through desaturation, elongation and a peroxisomal step to become DHA. Human tracer studies put that conversion in the low single-digit percentage range, and lower in men than in women. So the two are not equivalent inputs to the same pool, and flax raises the substrate side without reliably raising membrane DHA.

B12 is the cofactor for methionine synthase, and low B12 raises homocysteine. Secondary analyses of B-vitamin trials in older adults have reported that the effect on cognitive test scores differed by baseline omega-3 status. That is an association observed within trials, not a demonstrated causal interaction, and it concerns test scores rather than clinical outcomes.

5-methyltetrahydrofolate is the methyl donor methionine synthase uses, so folate status sets how efficiently homocysteine is remethylated. Reported interactions between B-vitamin supplementation and omega-3 status on cognitive test measures come from subgroup analyses in older adults. Subgroup findings generate a hypothesis and do not establish that the pair acts together.

Pyridoxal-5-phosphate is the cofactor for cystathionine beta-synthase, the enzyme that commits homocysteine to the transsulfuration route. The interest in pairing it with DHA comes from the same omega-3-status subgroup analyses in B-vitamin trials in older adults. That is an association within trial data, reported on markers and test scores.

Iodine is required to make thyroid hormone, which governs the timing of neuronal migration and myelination, while DHA is the structural fatty acid accumulating in the developing brain and retina across the third trimester. Prenatal formulas carry both because neither substitutes for the other. This is a statement about nutrient requirements, not a claim that a combination product improves a measured outcome.

Rhodopsin needs 11-cis-retinal as its chromophore, and the disc membrane that holds rhodopsin is among the most DHA-rich membranes in the body, which is what gives it the fluidity the conformational change requires. The two contribute different parts of the same structure. Both being required does not mean supplementing both changes vision measures in a person with adequate status.

Taurine is among the most abundant free amino acids in the retina and acts as an osmolyte and membrane stabiliser, and infant formula has long been supplemented with it for that reason. DHA occupies the membrane phospholipids of the same cells. They are compartment partners rather than pathway partners, and no combination trial is cited.

Carnitine palmitoyltransferase moves long-chain acyl groups into the mitochondrion, the route by which fatty acids are oxidised rather than stored in membranes. Very long-chain and highly unsaturated species like DHA are chain-shortened in the peroxisome first. Oxidation capacity is not the same as membrane incorporation, so this row is a metabolic relationship and not a benefit claim.

At high luminal calcium concentrations free fatty acids precipitate as insoluble calcium soaps and are excreted, an effect measured as increased faecal fat. The size of the effect on a supplemental DHA dose at ordinary calcium intakes has not been quantified in the material here. Separating a large calcium dose from an oil dose by a couple of hours removes the question entirely.

A viscous gel in the small intestine reduces the rate at which mixed micelles reach the absorptive surface, which is part of how viscous fibres lower cholesterol absorption. The same physics applies to any co-ingested fat. The measured effect on a small supplemental oil dose has not been quantified, so separating the two doses is a precaution rather than a documented necessity.

Plant sterols displace cholesterol from mixed micelles, which is the basis of their documented effect on cholesterol absorption. Micellar capacity is shared with other lipids, so a large sterol dose taken with an oil is a theoretical competitor. No measurement of an effect on DHA uptake is cited.

DHA and EPA are incorporated into platelet membranes and shift eicosanoid production toward less aggregatory species, a measurable change in platelet function. Nattokinase acts on fibrin. Two agents pushing bleeding time in the same direction should be flagged, especially for anyone on an anticoagulant or approaching surgery.

Garlic constituents inhibit platelet aggregation in ex vivo human testing, and omega-3 incorporation changes platelet eicosanoid output. The two effects are separate and are expected to add. This is a bleeding-risk flag to discuss with a prescriber, not a benefit to design around.

Curcuminoids inhibit cyclooxygenase and lipoxygenase activity in laboratory work, the same enzymes that process the arachidonic acid DHA competes with. Both also carry reported effects on platelet aggregation. The overlap is worth stating in both directions: a shared pathway for the mechanism, and additive bleeding tendency for the caution.

Gingerols inhibit thromboxane synthesis in laboratory preparations, though human data at culinary intakes are limited. Stacked with a high omega-3 intake the theoretical direction is additive. The flag matters most before a procedure or alongside an anticoagulant.

Bromelain is a proteolytic mixture reported to reduce platelet aggregation and fibrinogen in laboratory and small clinical work. The direction of effect matches that of a high omega-3 intake. The combined magnitude has not been measured.

Tocotrienols act as chain-breaking antioxidants in membranes and are described as more mobile within the lipid bilayer than tocopherol. That makes them relevant to protecting a DHA-rich membrane and to protecting the oil in the bottle. High tocotrienol intakes can displace alpha-tocopherol status, so the pair is worth stating rather than assuming.

Lipoic acid sits upstream in the antioxidant network that ultimately regenerates the tocopherol protecting polyunsaturated membrane lipids. It is amphipathic, so it acts in both the aqueous and lipid compartments. The endpoint measured in this work is oxidative stress markers, not a clinical result.

Resveratrol acts on NF-kappaB and Nrf2 signalling in cell models, routes that also respond to omega-3 derived mediators. Pairing them is a formulation choice in oxidative-stress products. The evidence is cell-model level and does not describe a measured combined effect in people.